537013-51-7

Basic information

• Product Name: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE
• Synonyms: 4-BROMO-2,6-DIFLUOROBENZALDEHYDE;4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE;Benzaldehyde, 4-broMo-2,6-difluoro-;4-Bromo-2,6-difluorobenzaldehyde 96%
• CAS NO: 537013-51-7
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 221
• EINECS: 1308068-626-2
• Product Categories: Benzaldehyde
• Mol File: 537013-51-7.mol

Chemical Properties

• Melting Point: 76-79°C
• Boiling Point: 231.4±40.0℃ (760 Torr)
• Flash Point: 93.7±27.3℃
• Appearance: /
• Density: 1.758±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.063mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE(537013-51-7)
• EPA Substance Registry System: 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE(537013-51-7)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 537013-51-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE is used as a key intermediate in the organic synthesis of various compounds. Its unique structure allows for a wide range of chemical reactions, making it a versatile building block for the creation of new molecules with diverse properties and applications.
Used in Pharmaceutical Industry:
4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE is used as a pharmaceutical intermediate for the development of new drugs. Its specific chemical properties enable the creation of novel drug candidates with potential therapeutic benefits. 4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE plays a crucial role in the research and development of pharmaceuticals, contributing to the advancement of medical treatments.
Used in Laboratory Research and Development:
4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE is employed in laboratory research and development as a valuable tool for exploring new chemical reactions and synthesizing novel compounds. Its unique structure and reactivity make it an essential component in the quest for new discoveries and innovations in the fields of chemistry and pharmaceuticals.
Used in Chemical Production Processes:
4-BROMO-2,6-DIFLUOROBENZYLALDEHYDE is utilized in chemical production processes as a vital intermediate for the synthesis of various chemicals and materials. Its unique properties and reactivity contribute to the efficient and cost-effective production of a wide range of products, from pharmaceuticals to specialty chemicals.

Synthesis

n-Butyl lithium (0.64ml, 1.2 mmol) was added drop wise to a solution of diisopropyl amine (0.25 mL, 1.5 mmol) in dry THF at -78°C under nitrogen atmosphere over a period of 5 minutes. The reaction mixture was stirred at -20°C for 30 minutes. To this was added 5-bromo-benzo[b]thiophene (200 mg, 0.938 mmol) in dry THF at -78°C, continued stirring for a further 30 minutes at -78°C, followed by the addition of N-chlorosuccinamide (225 mg, 1.68 mmol) in dry THF at -78°C. The resulting mixture was stirred at room temperature for 2 hours. The reaction was monitored by TLC (100% hexane). The reaction mixture was partitioned between ethyl acetate and saturated ammonium chloride. The organic layer was dried over sodium sulfate and concentrated to afford the crude product. Purification by column chromatography on silica gel (100% hexane) afforded the product. Preparation of Intermediate 4-Bromo-2,6-difluoro-benzaldehyde (I-26a): Using analogous reaction condition and reagents as described in Example 20 for the preparation of 1-20a above, 1-bromo-3,5-difluoro-benzene (2 g, 2.10.36 mmol) in THF was reacted with DMF (1.43 g,19.68 mmol), n-butyl lithium (1.56 ml, 12.4 mmol) and diisopropyl amine (0.57 mL, 15.5 mmol) to afford crude product. Purification by column chromatography on silica gel (2% ethyl acetate in hexane) afforded 1.35 g of the product (61% yield). 1H NMR (CDCl3, 300 MHz): δ 11.5-11.0 (s, 1H), 7.4-7.2 (dd, 2H).

InChI:InChI=1/C7H3BrF2O/c8-4-1-6(9)5(3-11)7(10)2-4/h1-3H

Upstream product

• 2591-86-8 N-Formylpiperidine 
• 461-96-1 3,5-difluorobromobenzene 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 64-19-7 acetic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 

Downstream Products

• 1027215-37-7 (4-bromo-2,6-difluoro-benzyl)-(3-methyl-butyl)-amine 
• 844850-00-6 ethyl 3-(4-bromo-2,6-difluorophenyl)-2-methylacrylate 
• 1318763-73-3 (E)-1-(1-benzyl-4-(3,5-difluoro-4'-methoxy-[1,1'-biphenyl]-4-yl)-2-methyl-1H-pyrrol-3-yl)ethanone oxime 
• 1318763-74-4 N-(1-benzyl-4-(3,5-difluoro-4'-methoxy-[1,1'-biphenyl]-4-yl)-2-methyl-1H-pyrrol-3-yl)acetamide 
• 1318763-72-2 1-(1-benzyl-4-(3,5-difluoro-4'-methoxy-[1,1'-biphenyl]-4-yl)-2-methyl-1H-pyrrol-3-yl)ethanone 
• 1318763-85-7 (E)-methyl 3-(4-(4-acetyl-1-benzyl-5-methyl-1H-pyrrol-3-yl)-3,5-difluorophenyl)acrylate 
• 1318763-84-6 (E)-ethyl 3-(4-(4-acetyl-1-benzyl-5-methyl-1H-pyrrol-3-yl)-3,5-difluorophenyl)acrylate 
• 1241918-55-7 (E)-3-(4-bromo-2,6-difluorophenyl)prop-2-enoic acid ethyl ester 
• 1426050-95-4 2-(4-bromo-2,6-difluorophenyl)-2-(4-ethyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)acetamide 
• 1426050-99-8 2-(4-bromo-2,6-difluorophenyl)-2-(4-cyclopropyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)acetamide 
• 1426050-93-2 2-(4-bromo-2,6-difluorophenyl)-2-hydroxyacetamide 
• 856767-09-4 4-bromo-2-fluoro-6-methoxy-benzaldehyde 
• 1354050-38-6 4-bromo-2,6-dimethoxy-benzaldehyde 
• 1427438-90-1 4-bromo-2-fluoro-6-hydroxybenzaldehyde 

Relevant articles and documents

HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound hasa high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

First-Generation Asymmetric Synthesis of the Selective Estrogen Receptor Degrader GDC-9545 (Giredestrant) Featuring a Highly Efficient Pictet-Spengler Reaction and a C-N Coupling Reaction

An asymmetric synthesis of the selective estrogen receptor degrader GDC-9545 (1) is described. The synthesis features a Friedel-Crafts indole functionalization and a strain-release aminoazetidine formation to construct the two key starting materials 2 and 4, respectively, a diastereoselective Pictet-Spengler reaction (98% yield, 95:5 dr) to assemble the tetrahydrocarboline core, and a highly efficient Pd-catalyzed C-N coupling (90% yield) using [t-BuBrettPhos Pd(allyl)]OTf as the catalyst and DBU as the base to furnish the final C-N bond. This expedient route produces GDC-9545·tartrate active pharmaceutical ingredient in a longest linear sequence of six steps in 37% overall yield with 99.0 area % HPLC purity without chromatographic purification.

Efficient Manufacturing Process for the Selective Estrogen Receptor Degrader GDC-9545 (Giredestrant) via a Crystallization-Driven Diastereoselective Pictet-Spengler Condensation

GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2- breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C-N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet-Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.

BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

The disclosure provides BRD9 bifunctional compounds of Formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodoma in-containing protein 9 (BRD9)

Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.

Micromolecular reversible BTK inhibitor for treating rheumatoid arthritis

The invention relates to a micromolecular reversible BTK inhibitor for treating rheumatoid arthritis, and specifically provides a compound. The compound is the compound as shown in a formula I, or a stereisomer, a geometrical isomer and a tautomer thereof, nitric oxide, aquo-complex, a solvate, a metabolite and pharmaceutically acceptable salts and prodrugs. The inventor finds that polysubstitutedquinolone compound or derivate thereof as shown in formula I can be used as the BTK inhibitor and is high in activity during treating rheumatoid arthritis.

Inhibiting effect of trisubstituted pyrimidine derivative on protein kinase

The invention discloses a trisubstituted pyrimidine derivative with a structure shown as general formula (I), and pharmaceutically acceptable salt, ester or solvent compound thereof. The derivative isa protein kinase inhibitor, can be used individually or in combination with other drugs for cancer treatment, and has tremendous clinical application value. General formula (I) is shown as the specification.

Pd-Catalyzed, ortho C-H Methylation and Fluorination of Benzaldehydes Using Orthanilic Acids as Transient Directing Groups

The direct, Pd-catalyzed ortho C-H methylation and fluorination of benzaldehydes have been accomplished using commercially available orthanilic acids as transient directing groups. In these reactions, the 1-fluoro-2,4,6-trimethylpyridinium salts can be either a bystanding F+ oxidant or an electrophilic fluorinating reagent. An X-ray crystal structure of a benzaldehyde ortho C-H palladation intermediate was obtained using triphenylphosphine as the stabilizing ligand.

Synthesis and Transformations of Functionalized Benzosiloxaboroles

The synthesis and characterization of a series of fluorinated benzosiloxaboroles bearing synthetically useful formyl and cyano groups is reported. These compounds have been obtained by multistep syntheses starting with simple halogenated benzenes. The general synthetic protocol was based on the generation of ortho-boronated aryldimethylsilanes which undergo dehydrogenative cyclization upon hydrolytic workup due to activation of the Si–H bond by the adjacent boronic group. In some cases the synergy of adjacent boron- and silicon-based functionalities resulted in an unexpected hydrosilylation of the CHO group under mild aqueous conditions. The reduction of a benzosiloxaborole derivative bearing the formyl group at the ortho position with respect to the boron atom resulted in a structural transformation reflecting the higher stability of the carboxaborole heterocycle with respect to its silicon counterpart. Thus, a unique heterocyclic system featuring a central 10-membered ring comprising two borasiloxane linkages was isolated.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.